Entry - #136630 - INTELLECTUAL DEVELOPMENTAL DISORDER, FRA12A TYPE - OMIM
 
# 136630

INTELLECTUAL DEVELOPMENTAL DISORDER, FRA12A TYPE


Alternative titles; symbols

MENTAL RETARDATION, FRA12A TYPE


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
12q13.12 Intellectual developmental disorder, autosomal dominant, FRA12A type 136630 AD 3 DIP2B 611379
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal dominant
SKIN, NAILS, & HAIR
Skin
- Bullous ichthyosiform erythroderma (in 1 patient)
- Hyperkeratosis (in 1 patient)
NEUROLOGIC
Central Nervous System
- Mental retardation
- Learning disabilities
- Global delay
- Seizures (in some patients)
Behavioral Psychiatric Manifestations
- Behavior problems
MISCELLANEOUS
- Variable phenotype
MOLECULAR BASIS
- Caused by a trinucleotide repeat expansion (CGG)n in the B homolog of the disco-interacting protein 2 homolog B gene (DIP2B, 611379.0001)
Intellectual developmental disorder, autosomal dominant - PS156200 - 66 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.11 Coffin-Siris syndrome 2 AD 3 614607 ARID1A 603024
1q21.3 White-Sutton syndrome AD 3 616364 POGZ 614787
1q21.3 GAND syndrome AD 3 615074 GATAD2B 614998
1q22 Intellectual developmental disorder, autosomal dominant 52 AD 3 617796 ASH1L 607999
1q44 Intellectual developmental disorder, autosomal dominant 22 AD 3 612337 ZBTB18 608433
2p25.3 Intellectual developmental disorder, autosomal dominant 39 AD 3 616521 MYT1L 613084
2q11.2 ?Intellectual developmental disorder, autosomal dominant 69 3 617863 LMAN2L 609552
2q23.1 Intellectual developmental disorder, autosomal dominant 1 AD 3 156200 MBD5 611472
3p25.3 Intellectual developmental disorder, autosomal dominant 23 AD 3 615761 SETD5 615743
3p21.31 Intellectual developmental disorder, autosomal dominant 70 AD 3 620157 SETD2 612778
3q22.3 Intellectual developmental disorder, autosomal dominant 47 AD 3 617635 STAG1 604358
3q26.32 Intellectual developmental disorder, autosomal dominant 41 AD 3 616944 TBL1XR1 608628
3q27.1 Intellectual developmental disorder 60 with seizures AD 3 618587 AP2M1 601024
4q31.1 Intellectual developmental disorder, autosomal dominant 50, with behavioral abnormalities AD 3 617787 NAA15 608000
5p15.2 Intellectual developmental disorder, autosomal dominant 63, with macrocephaly AD 3 618825 TRIO 601893
5p15.2 Intellectual developmental disorder, autosomal dominant 44, with microcephaly AD 3 617061 TRIO 601893
5q13.3 Intellectual developmental disorder, autosomal dominant 34 AD 3 616351 COL4A3BP 604677
5q32 Intellectual developmental disorder, autosomal dominant 53 AD 3 617798 CAMK2A 114078
5q33.2 Intellectual developmental disorder, autosomal dominant 67 AD 3 619927 GRIA1 138248
6p21.32 Intellectual developmental disorder, autosomal dominant 5 AD 3 612621 SYNGAP1 603384
6q13 Intellectual developmental disorder, autosomal dominant 46 AD 3 617601 KCNQ5 607357
6q14.3 Intellectual developmental disorder, autosomal dominant 64 AD 3 619188 ZNF292 616213
6q22.1 Intellectual developmental disorder, autosomal dominant 55, with seizures AD 3 617831 NUS1 610463
6q24.2 Intellectual developmental disorder, autosomal dominant 43 AD 3 616977 HIVEP2 143054
6q25.3 Coffin-Siris syndrome 1 AD 3 135900 ARID1B 614556
7p22.1 Intellectual developmental disorder, autosomal dominant 48 AD 3 617751 RAC1 602048
7p13 Intellectual developmental disorder, autosomal dominant 54 AD 3 617799 CAMK2B 607707
7q11.22 Intellectual developmental disorder, autosomal dominant 26 AD 3 615834 KIAA0442 607270
7q36.2 Intellectual developmental disorder, autosomal dominant 33 AD 3 616311 DPP6 126141
9p24 Intellectual developmental disorder, autosomal dominant 2 AD 4 614113 MRD2 614113
9q34.11 Intellectual developmental disorder, autosomal dominant 58 AD 3 618106 SET 600960
9q34.3 Kleefstra syndrome 1 AD 3 610253 EHMT1 607001
10p15.3 Intellectual developmental disorder, autosomal dominant 30 AD 3 616083 ZMYND11 608668
10q22.2 Intellectual developmental disorder, autosomal dominant 59 AD 3 618522 CAMK2G 602123
11p15.5 Vulto-van Silfout-de Vries syndrome AD 3 615828 DEAF1 602635
11q13.1 Coffin-Siris syndrome 7 AD 3 618027 DPF2 601671
11q13.1-q13.2 Schuurs-Hoeijmakers syndrome AD 3 615009 PACS1 607492
11q13.2 Intellectual developmental disorder, autosomal dominant 51 AD 3 617788 KMT5B 610881
11q24.2 Intellectual developmental disorder, autosomal dominant 4 AD 2 612581 MRD4 612581
12p13.1 Intellectual developmental disorder, autosomal dominant 6, with or without seizures AD 3 613970 GRIN2B 138252
12q12 Coffin-Siris syndrome 6 AD 3 617808 ARID2 609539
12q13.12 Intellectual developmental disorder, autosomal dominant, FRA12A type AD 3 136630 DIP2B 611379
12q13.2 Coffin-Siris syndrome 8 AD 3 618362 SMARCC2 601734
12q21.33 Intellectual developmental disorder, autosomal dominant 66 AD 3 619910 ATP2B1 108731
14q11.2 Intellectual developmental disorder, autosomal dominant 74 AD 3 620688 HNRNPC 164020
15q21.3 Intellectual developmental disorder, autosomal dominant 71, with behavioral abnormalities AD 3 620330 RFX7 612660
16p13.3 Intellectual developmental disorder, autosomal dominant 72 AD 3 620439 SRRM2 606032
16q22.1 Intellectual developmental disorder, autosomal dominant 21 AD 3 615502 CTCF 604167
16q24.3 Intellectual developmental disorder, autosomal dominant 3 AD 3 612580 CDH15 114019
17p13.1 Intellectual developmental disorder, autosomal dominant 62 AD 3 618793 DLG4 602887
17q21.2 Coffin-Siris syndrome 5 AD 3 616938 SMARCE1 603111
17q21.31 Koolen-De Vries syndrome AD 3 610443 KANSL1 612452
17q23.1 Intellectual developmental disorder, autosomal dominant 56 AD 3 617854 CLTC 118955
17q23.2 Intellectual developmental disorder, autosomal dominant 61 AD 3 618009 MED13 603808
17q23.2 Intellectual developmental disorder, autosomal dominant 57 AD 3 618050 TLK2 608439
18q12.3 Intellectual developmental disorder, autosomal dominant 29 AD 3 616078 SETBP1 611060
19p13.3 Intellectual developmental disorder, autosomal dominant 65 AD 3 619320 KDM4B 609765
19p13.2 Coffin-Siris syndrome 4 AD 3 614609 SMARCA4 603254
19q13.12 Intellectual developmental disorder, autosomal dominant 68 AD 3 619934 KMT2B 606834
19q13.2 Intellectual developmental disorder, autosomal dominant 45 AD 3 617600 CIC 612082
20q11.23 ?Intellectual developmental disorder, autosomal dominant 11 AD 3 614257 EPB41L1 602879
20q13.33 Intellectual developmental disorder, autosomal dominant 73 AD 3 620450 TAF4 601796
20q13.33 Intellectual developmental disorder, autosomal dominant 38 AD 3 616393 EEF1A2 602959
21q22.13 Intellectual developmental disorder, autosomal dominant 7 AD 3 614104 DYRK1A 600855
22q11.23 Coffin-Siris syndrome 3 AD 3 614608 SMARCB1 601607
22q12.3 ?Intellectual developmental disorder, autosomal dominant 10 AD 3 614256 CACNG2 602911

TEXT

A number sign (#) is used with this entry because of evidence that the FRA12A type of intellectual developmental disorder is caused by a heterozygous expanded CGG repeat in the 5-prime untranslated region of the DIP2B gene (611379) on chromosome 12q13.


Description

FRA12A is a folate-sensitive chromosomal fragile site prone to breakage. No consistent phenotype has been observed with FRA12A, and it can be inherited without phenotypic effect (Berg et al., 2000). However, impaired intellectual development with or without other anomalies has been described in patients with over 40% of cells expressing FRA12A (Winnepenninckx et al., 2007).


Clinical Features

Giraud et al. (1976) identified a chromosomal breakage point of chromosome 12q13 in a male patient with mental retardation and multiple congenital anomalies. An unaffected woman with the 12q13 fragile site had a baby with lethal arthrogryposis, but the baby did not have the 12q13 fragile site, leaving the phenotypic association undetermined.

Sutherland and Hinton (1981) reported a family in which 6 persons spanning 3 generations had a fragile site at chromosome 12q13. The fragile site was suppressed by folic acid and thymidine in lymphocyte culture. Although epidermolysis bullosa simplex (131900) also segregated in this family, the authors concluded that it was probably coincidence because at least 3 persons had one or the other disorder, but not both.

Smeets et al. (1985) reported a 15-year-old boy with mental retardation associated with a fragile site at 12q13 detected in 40% of metaphyses from peripheral lymphocytes. He also had seizures and behavioral problems. The unaffected mother and sister showed the same chromosomal fragility, at 26% and 22%, respectively. Kumar et al. (1986) reported a family in which heritable fragile 12q13 was an incidental finding in 3 women with cellular levels of 20 to 30%.

Berg et al. (2000) reported an 11-year-old girl with mental retardation, pulmonary stenosis, and bullous ichthyosiform erythroderma (BIE; 113800) associated with fragile 12q13 in 40% of lymphocytes. Her unaffected mother and maternal grandmother had 20 and 2%, respectively. In a review of reports of fragile 12q13 from the literature, Berg et al. (2000) concluded that individuals with greater than 40% of cells showing the fragile site have mental handicap, whereas those with lesser levels of fragile 12q13 may be unaffected, suggesting a dosage phenomenon.


Inheritance

The transmission pattern of FRA12A-type intellectual developmental disorder in the patients studied by Winnepenninckx et al. (2007) was consistent with autosomal dominant inheritance.


Molecular Genetics

From an overview of FRA12A cytogenetic expression in 41 individuals from 16 published families, Winnepenninckx et al. (2007) concluded that a high level of cytogenetic expression of this rare folate-sensitive fragile site was significantly associated with mental retardation. The patients included those reported by Smeets et al. (1985) and Berg et al. (2000). In patients with FRA12A, the authors identified an elongated polymorphic CGG repeat in the 5-prime untranslated region of the DIP2B gene (611379.0001), which encodes a protein with a DMAP1 (605077) binding domain, suggesting a role in DNA methylation machinery. DIP2B mRNA levels were halved in 2 subjects with FRA12A with mental retardation in whom the repeat expansion was methylated. In 2 individuals without mental retardation but with an expanded and methylated repeat, DIP2B expression was reduced to approximately two-thirds of the values observed in controls. A carrier of an unmethylated CGG repeat expansion showed increased levels of DIP2B mRNA, which suggested that the repeat elongation increases gene expression, as previously described for the fragile X-associated tremor/ataxia syndrome (300623). The data suggested that deficiency of DIP2B, a brain-expressed gene, may mediate the neurocognitive problems associated with FRA12A.


REFERENCES

  1. Berg, J., Grace, E., Teik, K. W., Hammond, H., Tidman, M., FitzPatrick, D. Bullous ichthyosiform erythroderma, developmental delay, aortic and pulmonary stenosis in association with a FRA12A. Clin. Dysmorph. 9: 213-219, 2000. [PubMed: 10955484, related citations] [Full Text]

  2. Giraud, F., Ayme, S., Mattei, J. F., Mattei, M. G. Constitutional chromosomal breakage. Hum. Genet. 34: 125-136, 1976. [PubMed: 1033912, related citations] [Full Text]

  3. Kumar, D., Clark, J. W., Blank, C. E., Patton, M. A. A family with craniofrontonasal dysplasia, and fragile site 12q13 segregating independently. Clin. Genet. 29: 530-537, 1986. [PubMed: 3742859, related citations] [Full Text]

  4. Smeets, D. F. C. M., Scheres, J. M. J. C., Hustinx, T. W. J. Heritable fragility at 11q13 and 12q13. Clin. Genet. 28: 145-150, 1985. [PubMed: 4042396, related citations] [Full Text]

  5. Sutherland, G. R., Hinton, L. Heritable fragile sites on human chromosomes. VI. Characterization of the fragile site at 12q13. Hum. Genet. 57: 217-219, 1981. [PubMed: 7194847, related citations] [Full Text]

  6. Winnepenninckx, B., Debacker, K., Ramsay, J., Smeets, D., Smits, A., FitzPatrick, D. R., Kooy, R. F. CGG-repeat expansion in the DIP2B gene is associated with the fragile site FRA12A on chromosome 12q13.1. Am. J. Hum. Genet. 80: 221-231, 2007. [PubMed: 17236128, images, related citations] [Full Text]


Cassandra L. Kniffin - updated : 8/28/2007
Victor A. McKusick - updated : 8/16/2007
Creation Date:
Victor A. McKusick : 6/4/1986
carol : 09/08/2023
carol : 04/12/2022
alopez : 10/07/2016
carol : 06/07/2016
wwang : 9/6/2007
ckniffin : 8/28/2007
alopez : 8/28/2007
terry : 8/16/2007
mark : 4/17/1996
mark : 4/17/1996
carol : 6/3/1992
carol : 5/29/1992
carol : 3/30/1992
supermim : 3/16/1992
supermim : 3/20/1990
ddp : 10/26/1989

# 136630

INTELLECTUAL DEVELOPMENTAL DISORDER, FRA12A TYPE


Alternative titles; symbols

MENTAL RETARDATION, FRA12A TYPE


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
12q13.12 Intellectual developmental disorder, autosomal dominant, FRA12A type 136630 Autosomal dominant 3 DIP2B 611379

TEXT

A number sign (#) is used with this entry because of evidence that the FRA12A type of intellectual developmental disorder is caused by a heterozygous expanded CGG repeat in the 5-prime untranslated region of the DIP2B gene (611379) on chromosome 12q13.


Description

FRA12A is a folate-sensitive chromosomal fragile site prone to breakage. No consistent phenotype has been observed with FRA12A, and it can be inherited without phenotypic effect (Berg et al., 2000). However, impaired intellectual development with or without other anomalies has been described in patients with over 40% of cells expressing FRA12A (Winnepenninckx et al., 2007).


Clinical Features

Giraud et al. (1976) identified a chromosomal breakage point of chromosome 12q13 in a male patient with mental retardation and multiple congenital anomalies. An unaffected woman with the 12q13 fragile site had a baby with lethal arthrogryposis, but the baby did not have the 12q13 fragile site, leaving the phenotypic association undetermined.

Sutherland and Hinton (1981) reported a family in which 6 persons spanning 3 generations had a fragile site at chromosome 12q13. The fragile site was suppressed by folic acid and thymidine in lymphocyte culture. Although epidermolysis bullosa simplex (131900) also segregated in this family, the authors concluded that it was probably coincidence because at least 3 persons had one or the other disorder, but not both.

Smeets et al. (1985) reported a 15-year-old boy with mental retardation associated with a fragile site at 12q13 detected in 40% of metaphyses from peripheral lymphocytes. He also had seizures and behavioral problems. The unaffected mother and sister showed the same chromosomal fragility, at 26% and 22%, respectively. Kumar et al. (1986) reported a family in which heritable fragile 12q13 was an incidental finding in 3 women with cellular levels of 20 to 30%.

Berg et al. (2000) reported an 11-year-old girl with mental retardation, pulmonary stenosis, and bullous ichthyosiform erythroderma (BIE; 113800) associated with fragile 12q13 in 40% of lymphocytes. Her unaffected mother and maternal grandmother had 20 and 2%, respectively. In a review of reports of fragile 12q13 from the literature, Berg et al. (2000) concluded that individuals with greater than 40% of cells showing the fragile site have mental handicap, whereas those with lesser levels of fragile 12q13 may be unaffected, suggesting a dosage phenomenon.


Inheritance

The transmission pattern of FRA12A-type intellectual developmental disorder in the patients studied by Winnepenninckx et al. (2007) was consistent with autosomal dominant inheritance.


Molecular Genetics

From an overview of FRA12A cytogenetic expression in 41 individuals from 16 published families, Winnepenninckx et al. (2007) concluded that a high level of cytogenetic expression of this rare folate-sensitive fragile site was significantly associated with mental retardation. The patients included those reported by Smeets et al. (1985) and Berg et al. (2000). In patients with FRA12A, the authors identified an elongated polymorphic CGG repeat in the 5-prime untranslated region of the DIP2B gene (611379.0001), which encodes a protein with a DMAP1 (605077) binding domain, suggesting a role in DNA methylation machinery. DIP2B mRNA levels were halved in 2 subjects with FRA12A with mental retardation in whom the repeat expansion was methylated. In 2 individuals without mental retardation but with an expanded and methylated repeat, DIP2B expression was reduced to approximately two-thirds of the values observed in controls. A carrier of an unmethylated CGG repeat expansion showed increased levels of DIP2B mRNA, which suggested that the repeat elongation increases gene expression, as previously described for the fragile X-associated tremor/ataxia syndrome (300623). The data suggested that deficiency of DIP2B, a brain-expressed gene, may mediate the neurocognitive problems associated with FRA12A.


REFERENCES

  1. Berg, J., Grace, E., Teik, K. W., Hammond, H., Tidman, M., FitzPatrick, D. Bullous ichthyosiform erythroderma, developmental delay, aortic and pulmonary stenosis in association with a FRA12A. Clin. Dysmorph. 9: 213-219, 2000. [PubMed: 10955484] [Full Text: https://doi.org/10.1097/00019605-200009030-00012]

  2. Giraud, F., Ayme, S., Mattei, J. F., Mattei, M. G. Constitutional chromosomal breakage. Hum. Genet. 34: 125-136, 1976. [PubMed: 1033912] [Full Text: https://doi.org/10.1007/BF00278880]

  3. Kumar, D., Clark, J. W., Blank, C. E., Patton, M. A. A family with craniofrontonasal dysplasia, and fragile site 12q13 segregating independently. Clin. Genet. 29: 530-537, 1986. [PubMed: 3742859] [Full Text: https://doi.org/10.1111/j.1399-0004.1986.tb00555.x]

  4. Smeets, D. F. C. M., Scheres, J. M. J. C., Hustinx, T. W. J. Heritable fragility at 11q13 and 12q13. Clin. Genet. 28: 145-150, 1985. [PubMed: 4042396] [Full Text: https://doi.org/10.1111/j.1399-0004.1985.tb00374.x]

  5. Sutherland, G. R., Hinton, L. Heritable fragile sites on human chromosomes. VI. Characterization of the fragile site at 12q13. Hum. Genet. 57: 217-219, 1981. [PubMed: 7194847] [Full Text: https://doi.org/10.1007/BF00282028]

  6. Winnepenninckx, B., Debacker, K., Ramsay, J., Smeets, D., Smits, A., FitzPatrick, D. R., Kooy, R. F. CGG-repeat expansion in the DIP2B gene is associated with the fragile site FRA12A on chromosome 12q13.1. Am. J. Hum. Genet. 80: 221-231, 2007. [PubMed: 17236128] [Full Text: https://doi.org/10.1086/510800]


Contributors:
Cassandra L. Kniffin - updated : 8/28/2007
Victor A. McKusick - updated : 8/16/2007

Creation Date:
Victor A. McKusick : 6/4/1986

Edit History:
carol : 09/08/2023
carol : 04/12/2022
alopez : 10/07/2016
carol : 06/07/2016
wwang : 9/6/2007
ckniffin : 8/28/2007
alopez : 8/28/2007
terry : 8/16/2007
mark : 4/17/1996
mark : 4/17/1996
carol : 6/3/1992
carol : 5/29/1992
carol : 3/30/1992
supermim : 3/16/1992
supermim : 3/20/1990
ddp : 10/26/1989